Type 2 diabetic patients with Graves' disease have more frequent and severe Graves' orbitopathy(798 views visite) Le Moli R, Muscia V, Tumminia A, Frittitta L, Buscema M, Palermo F, Sciacca L, Squatrito S, Vigneri R
Keywords Parole chiave: Diabetes, Graves, Ophthalmopath Severity, Adult, Article, Case Control Study, Controlled Study, Diabetic Patient, Diplopia, Disease Association, Disease Severity, Endocrine Ophthalmopathy, Enzyme Immunoassay, Female, Graves Disease, Human, Insulin Dependent Diabetes Mellitus, Major Clinical Study, Metabolism, Middle Aged, Non Insulin Dependent Diabetes Mellitus, Obesity, Priority Journal, Quality Of Life, Radioreceptor Assay, Retrospective Study, Risk Factor, Smoking, Vascular Disease,
Affiliations Affiliazioni: *** IBB - CNR ***
Department of Clinical and Molecular Biomedicine, Endocrinology Unit, Garibaldi-Nesima Medical Center, University of Catania, Via Palermo 636, Catania, Italy National Research Council (CNR), Department of Biostructures and Bioimmaging, Catania, Italy
References Riferimenti: Nathan, D.M., Bayless, M., Cleary, P., Genuth, S., Gubitosi-Klug, R., Lachin, J.M., Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions (2013) Diabetes, 62, pp. 3976-3986. , DCCT/EDIC Research Grou
(2011) ARNO report CINECA, , http://osservatorioarno.cineca.org, Available from:
Kalman, R., Mouritz, M.P., Diabetes mellitus: a risk factor in patients with Graves' orbitopathy (1999) Br J Opthalmol, 83, pp. 463-465
Zang, L., Grennan-Jones, F., Lane, C., Rees, D.A., Dayan, C.M., Ludgate, M., Adipose tissue depot-specific differences in the regulation of hyaluronan production of relevance to Graves' orbitopathy (2012) JCEM, 97, pp. 653-662
Valyasevi, R.W., Erickson, D.Z., Harteneck, D.A., Dutton, C.M., Heufelder, A.E., Jyonouchi, S.C., Differentiation of human orbital preadipocyte fibroblast induces expression of functional thyrotropin receptor (1999) J Clin Endocrinol Metab, 84, pp. 2557-2562
Stan, M., Bahn, R., Risk factors for development or deterioration of Graves' ophthalmopathy (2010) Thyroid, 20, pp. 777-783
Barker, J.M., Clinical review: type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening (2006) J Clin Endocrinol Metab, 91, pp. 1210-1217
Greco, D., Pisciotta, M., Gambina, F., Maggio, F., Graves' disease in subjects with type 1 diabetes mellitus: a prevalence study in Western Sicily (Italy) (2011) Prim Care Diabetes, 5, pp. 241-244
Dickinson, A.J., Perros, P., Controversies in the clinical evaluation of active thyroid - associated orbitopathy: use of detailed protocol with comparative photographs for objective assessment (2001) Clin Endocrinol, 55, pp. 283-303
Bartalena, L., Baldeschi, L., Dickinson, A., Eckstein, A., Kendall-Taylor, P., Marcocci, C., Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of GO (2008) Eur J Endocrinol, 158, pp. 273-285
Bahn, R.S., Gorman, C.A., Choice of therapy and criteria for assessing treatment outcome in thyroid - associated ophthalmopathy (1987) Endocrinol Metab Clin North Am, 16, pp. 391-407
Feldon, S.E., Lee, C.P., Muramatsu, S.K., Weiner, J.M., Quantitative computed tomography of Graves' ophthalmopathy: extraocular muscle and orbital fat in development of optic neuropathy (1985) Arch Ophthalmol, 103, pp. 213-215
Le Moli, R., Pluchino, A., Muscia, V., Regalbuto, C., Luciani, B., Squatrito, S., Graves' orbitopathy: extraocular muscle/total orbit area ratio is positively related to the clinical activity score (2012) Eur J Ophthalmol, 22, pp. 301-308
Mourits, M.P., Prummel, M.F., Wiersinga, W.M., Koornneef, L., Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy (1997) Clin Endocrinol, 47, pp. 9-14
Tanda, M.L., Piantanida, E., Liparulo, L., Veronesi, G., Lai, A., Sassi, L., Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center (2013) J Clin Endocrinol Metab, 98, pp. 1443-1449
De Kreutzenberg, S.V., Ceolotto, G., Papparella, I., Bortoluzzi, A., Semplicini, A., Dalla Man, C., Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanism (2010) Diabetes, 59, pp. 1006-1015
Sciacca, L., Vigneri, R., Tumminia, A., Frasca, F., Squatrito, S., Frittitta, L., Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients (2013) Nutr Metab Cardiovasc Dis, 23, pp. 808-815
Wiersinga, W.M., Autoimmunithy in Graves' ophthalnopathy: an unfortunate marriage between TSH receptor and IGF-1 receptor? (2011) J Clin Endocrinol Metab, 96, pp. 2386-2394
Van Zeijl, C.J., Fliers, E., van Koppen, C.J., Surovtseva, O.V., de Gooyer, M.E., Mourits, M.P., Effects of thyrotropin and thyrotropin-receptor-stimulating graves' disease immunoglobulin G on cyclin adenosine monophosphate and hyaluronan production in non differentiated orbital fibroblasts of Graves' ophthalmopathy patients (2010) Thyroid, 20, pp. 535-544
Smith, T.J., Hegedüs, L., Douglas, R.S., Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy (2012) Best Pract Res Clin Endocrinol Metab, 26, pp. 291-302
Papaconstantinou, J., Insulin/IGF-1 and ROS signaling pathway cross-talk in aging and longevity determination (2009) Mol Cell Endocrinol, 299, pp. 89-100
Zhang, L., Grennan-Jones, F., Draman, M.S., Lane, C., Morris, D., Dayan, C.M., Possible targets for non-immunosuppressive therapy of Graves' orbitopathy (2014) JECM, 99, pp. 1183-1190
Lee, S., Tsirbas, A., Goldberg, R.A., McCann, J.D., Thiazolidinedione induced thyroid associated orbitopathy (2007) BMC Ophthalmol, 7, p. 8
Dall'Asta, M., Derlindati, E., Ardigò, D., Zavaroni, I., Brighenti, F., Del Rio, D., Macrophage polarization: the answer to the diet/inflammation conundrum (2012) Nutr Metab Cardiovasc Dis, 22, pp. 387-392
Green, B.D., Irwin, N., Duffy, N.A., Gault, V.A., O'harte, F.P., Flatt, P.R., Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1 (2006) Eur Pharmacol, 547, pp. 192-199
Chilelli, N.C., Burlina, S., Lapolla, A., AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a "glycoxidation-centric" point of view (2013) Nutr Metab Cardiovasc Dis, 23, pp. 913-919
Huang, E.S., Laiteerapong, N., Liu, J.Y., John, P.M., Moffet, H.H., Karter, A.J., Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study (2014) JAMA Intern Med, 174, pp. 251-258
Cawood, T.J., Moriarty, P., O'Farrelly, C., O'Shea, D., Smoking and thyroid-associated ophthalmopathy: a novel explanation of biological link (2007) J Clin Endocrinol Metab, 92, pp. 59-64
Bartalena, L., Marcocci, C., Tanda, M.L., Manetti, L., Dell'Unto, E., Bartolomei, M.P., Cigarette smoking and treatment outcomes in Graves' ophthalmopathy (1998) Ann Intern Med, 129, pp. 632-635
Type 2 diabetic patients with Graves' disease have more frequent and severe Graves' orbitopathy
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(206 visite) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 DettagliEsporta in BibTeXEsporta in EndNote
Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, Maione AS, Condorelli G, Puca A, Trimarco B, Illario M, Iaccarino G * CaMK4 gene deletion induces hypertension(284 visite) J Am Heart Assoc Journal Of The American Heart Association (ISSN: 2047-9980), 2012; 1(4): N/D-N/D. Impact Factor:2.882 DettagliEsporta in BibTeXEsporta in EndNote
Antonini A, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U, Abbruzzese G, Ramat S, Petrone A, Quatrale R, Marconi R, Ceravolo R, Stefani A, Lopiano L, Zappia M, Capus L, Morgante L, Tamma F, Tinazzi M, Colosimo C, Guerra UP, Valzania F, Fagioli G, Distefano A, Bagnato A, Feggi L, Anna S, Maria Teresa Rosaria De Cr, Nobili F, Mazzuca N, Baldari S, Eleopra R, Bestetti A, Benti R, Varrone A, Volterrani D, Massa R, Stocchi F, Schillaci O, Dore F, Zibetti M, Castellano G, Battista SG, Giorgetti G * The relationship between cerebral vascular disease and parkinsonism: The VADO study(422 visite) Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1873-5126electronic), 2012; 18(6): 775-780. Impact Factor:3.274 DettagliEsporta in BibTeXEsporta in EndNote
Malvindi MA, Greco A, Conversano F, Figuerola A, Corti M, Bonora M, Lascialfari A, Doumari HA, Moscardini M, Cingolani R, Gigli G, Casciaro S, Pellegrino T, Ragusa A * MR Contrast Agents(230 visite) Small Animal Imaging, 2011 Jul 8; 21(13): 2548-2555. Impact Factor:1.784 DettagliEsporta in BibTeXEsporta in EndNote
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(409 visite) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 DettagliEsporta in BibTeXEsporta in EndNote